This latest report, Rimonabant: The first of the Cannabinoid blockbusters, forecasts the cannabinoid market in 2007 to generate $709 million in sales. This has grown 45% from 2006, when it was generating $386 million. The profile of the market will be raised considerably with Rimonabant, by Sanofi-Aventis, used to treat obesity and set to reach impressive sales in its first few years. Rimonabant, branded Acomplia and Zimulti (US), has now been approved for sale in all 25 countries of the European Union by the European Commission.

Marinol®, Cesamet®, Sativex ® and Rimonabant are all commercially-marketed cannabinoids. They treat a variety of conditions from weight-loss to pain relief. The introduction of cannabinoids into the pharmaceutical marketplace has begun, and attitudes to the drugs are changing. This increased acceptance will lead to greater market penetration, and the importance of the area will be seen with the first cannabinoid reaching blockbuster status before the end of the decade.

The growth of this class of products has not yet been realised. As a resource for developing new pharmaceutical products this area will continue to provide potential for the future, and there will be increased R&D efforts into this market. But what treatment areas will benefit? What are the products currently coming through the pipeline? Just how much market potential does this area offer?

This latest report, Rimonabant: The first of the Cannabinoid blockbusters, forecasts the cannabinoid market in 2007 to generate $709 million in sales. This has grown 45% from 2006, when it was generating $386 million. The profile of the market will be raised considerably with Rimonabant, by Sanofi-Aventis, used to treat obesity and set to reach impressive sales in its first few years. Rimonabant, branded Acomplia and Zimulti (US), has now been approved for sale in all 25 countries of the European Union by the European Commission. Make no mistake, major Pharma will not sit around and watch blockbusters being created without wanting to take some of the action. Will you be part of the success? Is this an area that your company is involved in? If not, is it an area you should be involved in? Find out today.

The report provides in-depth market analysis for current and potential products. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research and highlighting new indications. The study also assesses the challenges faced by potential companies. Attitudes to cannabinoids are changing - it will experience its first blockbuster.